{"id":"https://openalex.org/W2618775341","doi":"https://doi.org/10.1080/10245332.2017.1328165","title":"Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies","display_name":"Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies","publication_year":2017,"publication_date":"2017-05-25","ids":{"openalex":"https://openalex.org/W2618775341","doi":"https://doi.org/10.1080/10245332.2017.1328165","mag":"2618775341","pmid":"https://pubmed.ncbi.nlm.nih.gov/28545322"},"language":"en","primary_location":{"id":"doi:10.1080/10245332.2017.1328165","doi":"https://doi.org/10.1080/10245332.2017.1328165","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10245332.2017.1328165","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10245332.2017.1328165?needAccess=true","source":{"id":"https://openalex.org/S195061619","display_name":"Hematology","issn_l":"1024-5332","issn":["1024-5332","1027-7501","1607-8454"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320442","host_organization_name":"Maney Publishing","host_organization_lineage":["https://openalex.org/P4310320442"],"host_organization_lineage_names":["Maney Publishing"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/10245332.2017.1328165?needAccess=true","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057911528","display_name":"Andrzej J. Jakubowiak","orcid":"https://orcid.org/0000-0002-2597-6822","observed_orcids":["https://orcid.org/0000-0002-2597-6822"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Andrzej J. Jakubowiak","raw_affiliation_strings":["Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, The University of Chicago Medicine, Chicago, IL, USA","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080700451","display_name":"Jeanne M. DeCara","orcid":"https://orcid.org/0000-0002-8234-3132","observed_orcids":["https://orcid.org/0000-0002-8234-3132"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]},{"id":"https://openalex.org/I4210087865","display_name":"University of Chicago Medical Center","ror":"https://ror.org/0076kfe04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087865"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeanne M. DeCara","raw_affiliation_strings":["Department of Cardio-Oncology, The University of Chicago Medicine, Chicago, IL, USA"],"raw_orcid":"https://orcid.org/0000-0002-8234-3132","affiliations":[{"raw_affiliation_string":"Department of Cardio-Oncology, The University of Chicago Medicine, Chicago, IL, USA","institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012989885","display_name":"Khalid Mezzi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khalid Mezzi","raw_affiliation_strings":["Department of Clinical Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5057911528"],"corresponding_institution_ids":["https://openalex.org/I40347166","https://openalex.org/I4210087865"],"apc_list":{"value":2085,"currency":"GBP","value_usd":2557},"apc_paid":{"value":2085,"currency":"GBP","value_usd":2557},"fwci":3.5599,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":{"value":0.93523791,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"22","issue":"10","first_page":"585","last_page":"591"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9589999914169312,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.03660000115633011,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11638","display_name":"Cardiac tumors and thrombi","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/relapsed-multiple-myeloma","display_name":"relapsed multiple myeloma","score":0.9279999732971191},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.7509999871253967},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.972000002861023},{"id":"https://openalex.org/keywords/cardiac-risk-assessment","display_name":"cardiac risk assessment","score":0.8009999990463257},{"id":"https://openalex.org/keywords/cardiovascular-monitoring","display_name":"cardiovascular monitoring","score":0.7580000162124634},{"id":"https://openalex.org/keywords/hydration","display_name":"hydration","score":0.8460000157356262},{"id":"https://openalex.org/keywords/patient-education","display_name":"patient education","score":0.9629999995231628},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.7950000166893005}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.9939557909965515},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.851487398147583},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6157103776931763},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.612000584602356},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.583463191986084},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.479027658700943},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.47171422839164734},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.43821483850479126},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36272889375686646},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3535001277923584}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/10245332.2017.1328165","doi":"https://doi.org/10.1080/10245332.2017.1328165","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10245332.2017.1328165","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10245332.2017.1328165?needAccess=true","source":{"id":"https://openalex.org/S195061619","display_name":"Hematology","issn_l":"1024-5332","issn":["1024-5332","1027-7501","1607-8454"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320442","host_organization_name":"Maney Publishing","host_organization_lineage":["https://openalex.org/P4310320442"],"host_organization_lineage_names":["Maney Publishing"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology","raw_type":"journal-article"},{"id":"pmid:28545322","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28545322","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology (Amsterdam, Netherlands)","raw_type":"Case Reports"}],"best_oa_location":{"id":"doi:10.1080/10245332.2017.1328165","doi":"https://doi.org/10.1080/10245332.2017.1328165","is_oa":true,"landing_page_url":"https://doi.org/10.1080/10245332.2017.1328165","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/10245332.2017.1328165?needAccess=true","source":{"id":"https://openalex.org/S195061619","display_name":"Hematology","issn_l":"1024-5332","issn":["1024-5332","1027-7501","1607-8454"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320442","host_organization_name":"Maney Publishing","host_organization_lineage":["https://openalex.org/P4310320442"],"host_organization_lineage_names":["Maney Publishing"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/case-report","display_name":"Case Report"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"}],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W2618775341.pdf"},"referenced_works_count":28,"referenced_works":["https://openalex.org/W1869200070","https://openalex.org/W1985864219","https://openalex.org/W1992644002","https://openalex.org/W1995140209","https://openalex.org/W2022290696","https://openalex.org/W2037017311","https://openalex.org/W2039718569","https://openalex.org/W2041460501","https://openalex.org/W2072651194","https://openalex.org/W2081128344","https://openalex.org/W2087123368","https://openalex.org/W2102088366","https://openalex.org/W2112238086","https://openalex.org/W2118466253","https://openalex.org/W2128195747","https://openalex.org/W2131259241","https://openalex.org/W2134459196","https://openalex.org/W2161111822","https://openalex.org/W2191392447","https://openalex.org/W2193716145","https://openalex.org/W2257690238","https://openalex.org/W2275495359","https://openalex.org/W2395974339","https://openalex.org/W2536208744","https://openalex.org/W2555371382","https://openalex.org/W2579672219","https://openalex.org/W2742169549","https://openalex.org/W7128425332"],"related_works":["https://openalex.org/W2913572268","https://openalex.org/W2257690238","https://openalex.org/W2199138068","https://openalex.org/W2421188780","https://openalex.org/W3083771005","https://openalex.org/W2884976220","https://openalex.org/W2027152656","https://openalex.org/W4320494727","https://openalex.org/W2902908093","https://openalex.org/W2912170340"],"abstract_inverted_index":{"Objectives":[0],"and":[1,19,27,31,116,136,146,168],"importance:":[2],"Patients":[3],"with":[4,43,140,181],"multiple":[5],"myeloma":[6],"(MM)":[7],"have":[8,40],"an":[9,84],"increased":[10],"risk":[11,21,131],"of":[12,46,50,61,77,87,92,99,105,122,170,179],"cardiovascular":[13,62,79,123,134,142,172],"comorbidities":[14],"due":[15],"to":[16],"disease":[17],"burden":[18],"treatment-related":[20],"factors.":[22],"Proteasome":[23],"inhibitors,":[24],"including":[25,128],"bortezomib":[26],"carfilzomib,":[28],"are":[29,52,97],"effective":[30,183],"generally":[32],"well":[33],"tolerated":[34],"anti-MM":[35],"agents.":[36],"However,":[37],"cardiovascular-related":[38],"toxicities":[39],"been":[41],"reported":[42],"this":[44,182],"class":[45],"agents,":[47],"the":[48,58,90,103,110,164],"mechanisms":[49],"which":[51,174],"not":[53],"fully":[54],"understood.":[55],"We":[56,72],"discuss":[57,115],"practical":[59,118],"management":[60,121,169],"events":[63,80,124],"during":[64,125],"carfilzomib":[65,88,126],"therapy":[66,180],"for":[67,89,120,138,177],"relapsed":[68,93],"MM.":[69,94],"CLINICAL":[70],"PRESENTATION:":[71],"present":[73],"two":[74,111],"adapted":[75,112],"cases":[76,96],"treatment-emergent":[78],"in":[81,156,163],"patients":[82,139],"receiving":[83],"approved":[85],"regimen":[86],"treatment":[91],"These":[95],"reflective":[98],"clinical":[100],"practice":[101],"at":[102],"University":[104],"Chicago":[106],"Medicine.":[107],"INTERVENTION:":[108],"Using":[109],"cases,":[113],"we":[114],"illustrate":[117],"approaches":[119],"therapy,":[127],"baseline":[129],"cardiac":[130],"assessment,":[132],"hydration,":[133],"monitoring,":[135],"interventions":[137],"suspected":[141],"signs":[143],"or":[144],"symptoms,":[145],"patient":[147],"education.":[148],"CONCLUSION:":[149],"Carfilzomib":[150],"has":[151],"a":[152],"favorable":[153],"benefit-risk":[154],"profile":[155],"MM;":[157],"adopting":[158],"proactive":[159],"practices":[160],"can":[161],"assist":[162],"prevention,":[165],"early":[166],"detection,":[167],"carfilzomib-associated":[171],"events,":[173],"may":[175],"allow":[176],"continuation":[178],"agent.":[184]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-06-05T00:00:00"}